The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use.

Physicians and analysts have commented that the health risks associated with Pradaxa are significant. As Forbes reports, the FDA plans to address these lingering concerns. The FDA posted a request for public comment on a study it plans to conduct regarding the safety of Pradaxa. The study will “assess systematically the rates of bleeding and thromboembolic outcomes associated with the use of dabigatran and warfarin for patients with atrial fibrillation.” The major purpose of the study is to identify groups of patients who are at high risk for major bleeding events with Pradaxa.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.